AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2011
Dec 16, 2011
29864_dirs_2011-12-16_0966aaf0-ec29-4a49-ab1f-bd93a2a4cb46.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2011-12-14
Reporting Person: LEIDEN JEFFREY M (Director, CEO Designate)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2011-12-14 | Common Stock | A | 50017 | $0.01 | Acquired | 52617 | Direct |
| 2011-12-14 | Common Stock | A | 133378 | $0.01 | Acquired | 185995 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2011-12-14 | Stock Option | $29.99 | A | 458108 | Acquired | 2021-12-13 | Common Stock (458108) | Direct |
Footnotes
F1: Stock grant under 2006 Stock and Option Plan vesting on December 14, 2014.
F2: Performance-based stock grant under 2006 Stock and Option Plan that will vest only if Vertex meets certain performance objectives. Up to 50% of the grant will vest on the date of the Company's first regularly scheduled board meeting in 2013 and up to 50% of the grant will vest on the date of the Company's 2014 Annual Meeting of its shareholders.
F3: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 12/14/2011.